Comparing microwave ablation and liver surgery for treating intrahepatic cholangiocarcinoma
Microwave Ablation Versus Liver Resection for Intrahepatic Cholangiocarcinoma Within Milan Criteria
Chinese PLA General Hospital · NCT06462742
This study is testing whether microwave ablation can be a good first treatment option for people with a specific type of liver cancer compared to traditional liver surgery.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 1000 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Chinese PLA General Hospital (other) |
| Locations | 1 site (Beijing, Beijing Municipality) |
| Trial ID | NCT06462742 on ClinicalTrials.gov |
What this trial studies
This observational study aims to evaluate the effectiveness of microwave ablation (MWA) compared to liver resection (LR) in patients with intrahepatic cholangiocarcinoma (iCCA). It will analyze survival outcomes and identify risk factors associated with both treatment methods. Data will be collected from multiple hospitals for patients who meet specific criteria, focusing on those with tumors within the Milan criteria. The study seeks to determine if MWA can serve as a viable first-line treatment option for iCCA.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older with pathologically diagnosed iCCA who meet the Milan criteria for treatment.
Not a fit: Patients with tumors that exceed the Milan criteria or those with other malignancies may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide an alternative treatment option for patients with iCCA, potentially improving survival rates.
How similar studies have performed: While thermal ablation has been established for hepatocellular carcinoma, evidence for its efficacy in iCCA is limited, making this approach relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. pathologically diagnosed iCCA based on the WHO classifications; 2. curative-intent liver resection or microwave ablation; 3. tumor within Milan criteria, namely single tumor ≤5cm in maximum diameter; multiple tumors ≤3 in number and each ≤3cm; no evidence of major vascular/hilar invasion, extrahepatic/lymphatic metastasis or other malignancies; 4. age ≥18 years. Exclusion Criteria: Patients not meeting any one of the inclusion criteria were excluded.
Where this trial is running
Beijing, Beijing Municipality
- Chinese PLA General Hospital — Beijing, Beijing Municipality, China (RECRUITING)
Study contacts
- Study coordinator: Chuan Pang, Doctor
- Email: pcpang117@163.com
- Phone: +86-18910527022
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Overall Survival, Disease-free Survival